Population-based study of long-term mortality risk associated with clozapine use among patients with schizophrenia
The British Journal of Psychiatry · 2026-08 · 229 (2) · 140-148
DOI: 10.1192/bjp.2025.10312 ↗Kurz gefasst
Fachartikel in der Zeitschrift The British Journal of Psychiatry, online erschienen am 04.07.2025. Verfasst von Huiquan Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Clozapine, Antipsychotic Agents, Schizophrenia, Schizophrenia, Treatment-Resistant. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Patients with schizophrenia have a significantly elevated risk of mortality. Clozapine is effective for treatment-resistant schizophrenia, but its use is limited by side-effects. Understanding its association with mortality risk is crucial.
Aims
To investigate the associations of clozapine with all-cause and cause-specific mortality risk in schizophrenia patients.
Method
In this 18-year population-based cohort study, we retrieved electronic health records of schizophrenia patients from all public hospitals in Hong Kong. Clozapine users (ClozUs) comprised schizophrenia patients who initiated clozapine treatment between 2003 and 2012, with the index date set at clozapine initiation. Comparators were non-clozapine antipsychotic users (Non-ClozUs) with the same diagnosis who had never received a clozapine prescription. They were 1:2 propensity score matched with demographic characteristics and physical and psychiatric comorbidities. ClozUs were further defined according to continuation of clozapine use and co-prescription of other antipsychotics (polypharmacy). Accelerated failure time (AFT) models were used to estimate the risk of all-cause and cause-specific mortality (i.e. suicide, cardiovascular disease, infection and cancer).
Results
This study included 9,456 individuals (mean (s.d.) age at the index date: 39.13 (12.92) years; 50.73% females; median (interquartile range) follow-up time: 12.37 (9.78–15.22) years), with 2020 continuous ClozUs, 1132 discontinuous ClozUs, 4326 continuous non-ClozUs and 1978 discontinuous Non-ClozUs. Results from adjusted AFT models showed that continuous ClozUs had a lower risk of suicide mortality (acceleration factor 3.01; 99% CI: 1.41–6.44) compared with continuous Non-ClozUs. Continuous ClozUs with co-prescription of other antipsychotics exhibited lower risks of suicide mortality (acceleration factor 3.67; 1.41–9.60) and all-cause mortality (acceleration factor 1.42; 1.07–1.88) compared with continuous Non-ClozUs. No associations were found between clozapine and other cause-specific mortalities.
Conclusions
These results add to the existing evidence on the effectiveness of clozapine, particularly its anti-suicide effects, and emphasise the need for continuous clozapine use for suitable patients and the possible benefit of clozapine polypharmacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China.
- School of Public Health Sciences, University of Waterloo, Waterloo, Canada.
- Department of Educational Psychology, The Chinese University of Hong Kong, Hong Kong SAR, China.
- Department of Psychiatry, The University of British Columbia, Vancouver, Canada.
- Flinders Health and Medical Research Institute, Flinders University, Adelaide, Australia.
- Department of Psychiatry, Monash University, Melbourne, Australia.
ORCID-Profile: Huiquan Zhou, Hao Luo, Jennifer Yee-Man Tang, Wing Chung Chang, Simon Sai Yu Lui, Sherry Kit Wa Chan
Zitieren
APA
Zhou, H., Luo, H., Tang, J. Y., Honer, W. G., Bastiampillai, T., Zhou, J., Taipale, H., Chang, W. C., Lui, S. S. Y., Lee, E. H. M., & Chan, S. K. W. (2026). Population-based study of long-term mortality risk associated with clozapine use among patients with schizophrenia. The British Journal of Psychiatry, 229(2), 140-148. https://doi.org/10.1192/bjp.2025.10312
Vancouver
Zhou H, Luo H, Tang JY, Honer WG, Bastiampillai T, Zhou J, et al. Population-based study of long-term mortality risk associated with clozapine use among patients with schizophrenia. The British Journal of Psychiatry. 2026;229(2):140-148. doi:10.1192/bjp.2025.10312
BibTeX
@article{Zhou2026,
author = {Zhou, Huiquan and Luo, Hao and Tang, Jennifer Yee-Man and Honer, William G and Bastiampillai, Tarun and Zhou, Jiayi and Taipale, Heidi and Chang, Wing Chung and Lui, Simon Sai Yu and Lee, Edwin Ho Ming and Chan, Sherry Kit Wa},
title = {Population-based study of long-term mortality risk associated with clozapine use among patients with schizophrenia},
journal = {The British Journal of Psychiatry},
year = {2026},
volume = {229},
number = {2},
pages = {140--148},
doi = {10.1192/bjp.2025.10312}
}
EUVIMED